Studies, approvals and policy changes, summarised in plain words, each one linked to the original source.
On October 15, 2026, a government website showed that the Department of Health and Human Services had sent a peptide “interim access policy” to the White House for review. The policy text has not been published. Reporting describes it as a way to let licensed compounding pharmacies make some popular peptides, BPC-157 among them, for a limited time while the FDA works out permanent rules.
Read the post →Curodont is a peptide treatment that dentists brush onto an early cavity, the chalky white spot that comes before a hole. It takes a few minutes, with no drilling and no needles. Its maker, vVardis, says it has now been sold to more than 20,000 of the roughly 110,000 general dental practices in the US, and in October 2026 the company filed to list on the New York Stock Exchange.
Read the post →On October 22, 2026, Gilead Sciences agreed to pay $1.275 billion upfront for HCXT-2001, an oral peptide from the Shanghai biotech PepStar Therapeutics. It is being developed for inflammatory bowel disease, with psoriasis a possible second use. The deal is expected to close by the end of 2026.
Read the post →It depends on the peptide and how it reaches you. FDA-approved peptide drugs are legal with a prescription. Compounded peptides are legal only when the ingredient is eligible for compounding, and in 2026 the list of eligible peptides has been moving. Products sold online as “for research use only” are a separate category again. This is a description of where things stand, not legal advice.
Read the post →In TRIUMPH-1, published in the New England Journal of Medicine on September 29, 2026, adults without diabetes on the highest dose of retatrutide (12 mg once a week) lost 25.0% of their body weight on average over 80 weeks, against 3.9% on placebo Studied in humans. Three other Phase 3 trials, in knee osteoarthritis, type 2 diabetes and heart disease, reported large reductions too. Retatrutide is not approved; Eli Lilly says it plans to submit it to the FDA in the first quarter of 2027.
Read the post →On December 22, 2025, the FDA approved the Wegovy pill, a once-daily 25 mg tablet of semaglutide, the same peptide as the Wegovy injection. It was the first GLP-1 medicine taken by mouth for weight management. In its main trial, adults lost 13.6% of their body weight on average over 64 weeks, against 2.2% on placebo Studied in humans.
Read the post →